EXACT Therapeutics AS

OB:EXTX Stock Report

Market Cap: NOK 182.9m

EXACT Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Per Walday

Chief executive officer

NOK 2.8m

Total compensation

CEO salary percentage80.2%
CEO tenure2.4yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Aug 09
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

Apr 20
Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Sep 07
We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

May 06
We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Dec 30
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

Sep 15
Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

Jan 31
EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Aug 21
We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

May 21
We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

CEO Compensation Analysis

How has Per Walday's remuneration changed compared to EXACT Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-NOK 55m

Mar 31 2024n/an/a

-NOK 52m

Dec 31 2023NOK 3mNOK 2m

-NOK 48m

Sep 30 2023n/an/a

-NOK 42m

Jun 30 2023n/an/a

-NOK 36m

Mar 31 2023n/an/a

-NOK 38m

Dec 31 2022NOK 2mNOK 1m

-NOK 40m

Compensation vs Market: Per's total compensation ($USD255.78K) is about average for companies of similar size in the Norwegian market ($USD300.00K).

Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.

CEO

Per Walday (64 yo)

2.4yrs

Tenure

NOK 2,833,302

Compensation

Dr. Per Walday, Ph D., has been the Chief Executive Officer at PCI Biotech AS since 2008. He serves as Chief Executive Officer at EXACT Therapeutics AS since June 5, 2022.Dr. Walday had been the Chief Exe...

Leadership Team

NamePositionTenureCompensationOwnership
Per Walday
Chief Executive Officer2.4yrsNOK 2.83mno data
Masha Paule Nathalie Stromme
Vice-Chair of the Board9.8yrsNOK 445.00kno data
Svein Kvåle
Co Founder & COOno dataNOK 1.65m9.43%
NOK 17.2m
John Edminson
Chief Financial Officer2.1yrsNOK 2.02mno data
Amir Snapir
Chief Medical Officer2.2yrsNOK 2.66mno data
Caspar Foghsgaard
Chief Business Officerless than a yearNOK 250.00kno data
Per Sontum
Founderno dataNOK 2.49m5.99%
NOK 11.0m
Ragnar Bendicksen
Vice President of Technology2.6yrsno datano data

2.3yrs

Average Tenure

Experienced Management: EXTX's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Masha Paule Nathalie Stromme
Vice-Chair of the Board9.8yrsNOK 445.00kno data
William Castell
Director6.8yrsNOK 275.00k1.05%
NOK 1.9m
Anders Wold
Chair of the Board2.9yrsNOK 510.00kno data
Ann-Tove Kongsnes
Director3.4yrsNOK 260.00kno data

5.1yrs

Average Tenure

Experienced Board: EXTX's board of directors are considered experienced (5.1 years average tenure).